chronic Hepatitis B
Conditions
Interventions
Treatment group:None
Control group:None
Sponsors
West China hospital of Sichuan University,China
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Detectable hepatitis B surface antigen (HBsAg) for at least 24 weeks, with negative HBeAg and positive hepatitis B e antibody (HBeAb); (2) Continously normal ALT(at least three values of ALT below the upper limit of normal (ULN) within 1 year and at least 3 months apart); (3) Detectable serum HBV DNA (>= 20 IU/mL); (4) HBV treatment-naïve patients, without previous NA or interferon treatment; (5) Volunteering to participate in the study and promise to cooperate in completing the follow-up.
Exclusion criteria
Exclusion criteria: (1)Pregnant or lactating women; (2) Age < 18 years old; (3)Coinfection with other virus, including hepatitis C virus (HCV), hepatitis D virus (HDV), cytomegalovirus(CMV), epstein-Barr virus(EBV), or human immunodeficiency virus(HIV); (4) Suffered from other forms of liver disease, including alcoholic, autoimmune or biliary disease; (5) advanced or significant liver fibrosis by transient elastography or liver biopsy; (6) confirmed liver cirrhosis, HCC or liver transplant patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in level of serum HBV DNA ;Rate of HBeAg seroconversion;Level of serum HBsAg;Scores of liver fibrosis(APRI, FIB-4);Liver stiffness;Scores of health-related quality of life; | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of negative serum HBsAg;Rate of liver nodules;Rate of liver cirrhosis;Rate of hepatocellular carcinoma ; | — |
Countries
China
Contacts
Public ContactEnqiang Chen
West China Hospital of Sichuan University
Outcome results
None listed